Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of LMN-401 in Individuals With Ileostomies
NCT06556940Phase 1Recruiting
- Sponsor
- Lumen Bioscience
- Start
- Dec 2024
- Primary completion
- Oct 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of LMN-GI-EEC-401 in traveler's diarrhea (TD) (4 arms), sponsored by Lumen Bioscience. Primary endpoint: Quantification of LMN-401 components in ileostomy material. Started Dec 2024; status: recruiting.
02
Drugs
LMN-GI-EEC-401
03
Conditions
traveler's diarrhea (TD)
Beyond the preview
Go deeper on NCT06556940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06556940.